In addition to the experience you expect from a major global agency (therapy areas, brand lifecycles, research audiences), we have a special understanding and strong knowledge of the US domestic market.

Expertise in pricing that accounts for access and payor issues from a US perspective, including the impact of bodies that affect these issues, for example:

• Market access and payor
• Medicare, including Medicare Part D
• Medicaid
• Managed care
• Hospital P&T access

Accounting for the likely impact if drugs are reimbursed under various systems including:

• Diagnosis related groups (DRG)
• Procedural codes (CPT)
• ICD-9

We determine the impact of these factors on all types of pharmaceutical agents and devices, including categories such as:

• Mass market agents
• Specialist-use drugs
• Targeted therapies
• Orphan drugs

For more details on US domestic experience, please call:

Marlene de la Cruz (Phone +1 215 489 9200)

Amy Abel (Phone +1 215 489 9200)

Jeff Nelson (Phone +1 215 489 9200)